Literature DB >> 15378511

Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole.

Federica Albo1, Massimo Pieri, Cristina Zona.   

Abstract

We investigated the interaction of riluzole, a therapeutic agent used in amyotrophic lateral sclerosis (ALS), with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor channels in mouse spinal motor neurons in culture using whole-cell patch-clamp recording techniques. Kainate elicited concentration-dependent (EC(50) = 35 microM) inward currents in all the patched cells. These responses were mediated primarily through the activation of AMPA receptors with a negligible contribution from kainate receptors, because bath application of 100 microM GYKI53655, a potent noncompetitive AMPA receptor antagonist, completely blocked the kainate-induced currents. Riluzole (0.5-100 microM) reduced in a dose-dependent manner the kainate-induced currents with an IC(50) of 1.54 microM in all tested neurons (n = 25) and this effect was found to be reversible. The response to kainate decreased in the presence of 1 microM riluzole in all spinal motor neurons tested, without changing its EC(50), indicating a noncompetitive mechanism of inhibition. The amplitude of the responses induced by kainate under control condition and during riluzole was a linear function of the membrane potential. The reversal potential of the current was not significantly different in the two experimental conditions, whereas the total conductance of the motor neurons for the currents induced by 100 microM kainate was reduced significantly in the presence of 1 microM riluzole (P < 0.05). These results reveal an interaction of riluzole with glutamatergic neurotransmission in spinal cord motor neurons and can contribute to explain its beneficial effect in the ALS treatment. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378511     DOI: 10.1002/jnr.20244

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  17 in total

1.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 2.  Genetic inactivation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission?

Authors:  Asa Wallén-Mackenzie; Hanna Wootz; Hillevi Englund
Journal:  Ups J Med Sci       Date:  2010-02       Impact factor: 2.384

3.  Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.

Authors:  Hitoshi Sakurai; Christina Dording; Albert Yeung; Simmie Foster; Felipe Jain; Trina Chang; Nhi-Ha Trinh; Richard Bernard; Sean Boyden; Syed Z Iqbal; Samuel T Wilkinson; Sanjay J Mathew; David Mischoulon; Maurizio Fava; Cristina Cusin
Journal:  J Affect Disord       Date:  2019-07-02       Impact factor: 4.839

4.  An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy.

Authors:  Bradley R Foerster; Martin G Pomper; Brian C Callaghan; Myria Petrou; Richard A E Edden; Mona A Mohamed; Robert C Welsh; Ruth C Carlos; Peter B Barker; Eva L Feldman
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

Review 5.  Stronger is not always better: could a bodybuilding dietary supplement lead to ALS?

Authors:  Marin Manuel; C J Heckman
Journal:  Exp Neurol       Date:  2010-12-15       Impact factor: 5.330

Review 6.  Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.

Authors:  Jing Wang; Liang Jing; Juan-Carlos Toledo-Salas; Lin Xu
Journal:  Neurosci Bull       Date:  2014-12-06       Impact factor: 5.203

7.  Activation of glutamate transporters in the locus coeruleus paradoxically activates descending inhibition in rats.

Authors:  Ken-ichiro Hayashida; Renee A Parker; James C Eisenach
Journal:  Brain Res       Date:  2010-01-06       Impact factor: 3.252

Review 8.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.

Authors:  Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2018-05-15       Impact factor: 9.261

10.  Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  In-Soo Joo; Dong-Hoon Hwang; Jung-Im Seok; Sang-Kun Shin; Seung-Up Kim
Journal:  J Clin Neurol       Date:  2007-12-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.